S3 Episode 4: Antibody-Drug Conjugates and Lung Cancer S3 Episode 4: Antibody-Drug Conjugates and Lung Cancer
Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2024 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Novant Health deploys high-tech robotics for lung cancer treatment
Novant Health recently implemented new robotics technology to improve diagnostics and treatment for lung cancer patients. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 9, 2024 Category: Biotechnology Authors: Elise Franco Source Type: news
Exacerbations Predict Poor Outcomes in NSCLC With IIP Exacerbations Predict Poor Outcomes in NSCLC With IIP
Treatment regimens for non –small cell lung cancer were independent predictors of chemotherapy-triggered exacerbations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2024 Category: Consumer Health News Tags: Pulmonary Medicine Clinical Summary Source Type: news
Novant Health deploys high-tech robotics for lung cancer treatment
Novant Health recently implemented new robotics technology to improve diagnostics and treatment for lung cancer patients. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 8, 2024 Category: Pharmaceuticals Authors: Elise Franco Source Type: news
Polarean touts recent xenon MRI research
MRI contrast agent developer Polarean is highlighting upcoming poster presentations at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS) May 17-18 in San Diego.
Nearly 18 months after the company's approval of Xenoview (xenon, Xe-129 hyperpolarized) for oral inhalation during MRI, Polarean's research includes 33 presentations from 10 different sites and multiple categories such as asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, hematopoietic stem cell transplant, lung cancer resection, radiation-induced lung injury, pulmonary arterial hypertension, and thoracic insuffic...
Source: AuntMinnie.com Headlines - May 8, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
ISMRM: Combining brain MRI, CT radiomics improves lung cancer prognosis
This study [suggests] that survival prediction can be enhanced by combining features of brain metastasis MRI and lung cancer CT," he concluded. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 8, 2024 Category: Radiology Authors: Kate Madden Yee Tags: MRI Neuroradiology ISMRM 2024 Source Type: news
Drug Trials Snapshots: AUGTYRO
AUGTYRO is a drug used to treat adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 3, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Novartis bets on actinium RLT with $1B Mariana Oncology acquisition
Novartis has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company that develops novel radioligand therapies (RLTs) for cancer.
Watertown, MA-based Mariana Oncology's portfolio crosses a range of solid tumor indications such as breast, prostate, and lung cancer and includes development candidate MC-339, an actinium-based RLT being investigated in small cell lung cancer, according to Novartis. In September 2023, Mariana announced $175 million in Series B financing from Atlas Venture, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, and Eli Lilly and C...
Source: AuntMinnie.com Headlines - May 2, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Radiation Oncology Source Type: news
Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC
(MedPage Today) -- Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to a phase II trial from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 1, 2024 Category: Hematology Source Type: news
Volumetric CT helps predict lung-lobectomy complications
Volumetric CT imaging analysis shows promise for helping clinicians determine pre- and postoperative lung function in lung cancer patients undergoing pulmonary lobectomy, researchers have found.
A team led by Zhifu Xu, PhD, of ZhangJiaKou First Hospital in Hebei, China, reported that the technique may also help predict postsurgery complication occurrence. The results were published April 30 in BMC Medical Imaging.
"[We found that] lung function detected from CT volumetric analysis [is] consistent with those from the lung function measurements in lung cancer patients … [suggesting that] CT volumetric imaging can be a fu...
Source: AuntMinnie.com Headlines - May 1, 2024 Category: Radiology Authors: Kate Madden Yee Tags: CT Chest Radiology Source Type: news
Paul Auster, Prolific Author and Brooklyn Literary Star, Dies at 77
Paul Auster, the prolific novelist, memoirist and screenwriter who rose to fame in the 1980s with his postmodern reanimation of the noir novel and who endured to become one of the signature New York writers of his generation, died of complications from lung cancer at his home in Brooklyn on…#paulauster #brooklyn #jackilyden #newjersey #parkslope (Source: Reuters: Health)
Source: Reuters: Health - May 1, 2024 Category: Consumer Health News Source Type: news
Call to Action: Prioritizing Cure in Lung Cancer Call to Action: Prioritizing Cure in Lung Cancer
Dr Mark Kris discusses the prioritization of cure and the impact on clinical trial design.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 29, 2024 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news
What your cough could really mean, from THAT irritating 'dry' tickle to the 'wet' one that leaves you spluttering mucus
London-based GP Dr Hana Patel says she often sees patients who have had a pesky dry cough after a virus or cold. But if your cough won't budge, it could be a sign of lung cancer . (Source: the Mail online | Health)
Source: the Mail online | Health - April 28, 2024 Category: Consumer Health News Source Type: news
Closing Gender-Based Disease Disparities Starts in the Lab
(MedPage Today) -- Despite the fact men have lower life expectancy than women and are at a higher risk of developing serious health conditions like heart disease and lung cancer, women spend 25% more of their lives in poor health compared to men... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 27, 2024 Category: American Health Source Type: news
CHMP recommends EU approval of Roche ’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
If approved, Alecensa will be the first and only ALK inhibitor approved for people with resected ALK-positive early-stage non-small cell lung cancer (NSCLC)The positive recommendation is based on results from the Phase III ALINA study where Alecensa showed an unprecedented 76% reduction in the risk of disease recurrence or death, compared to adjuvant chemotherapy1With about half of people living with early-stage NSCLC experiencing disease recurrence or death following surgery, Alecensa could minimise the risk by treating NSCLC before it has spread2Basel, 26 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today th...
Source: Roche Investor Update - April 26, 2024 Category: Pharmaceuticals Source Type: news
